Whole-genome plasma DNA sequencing in CRC patients under anti-EGFR therapy
In this study we performed whole genome sequencing of plasma DNA (plasma-Seq) of 19 plasma-DNA samples from a total of 10 patients treated with anti-EGFR therapy. We demonstrated that development of resistance to anti-EGFR therapies is frequently associated with focal amplifications of KRAS, MET, and ERBB2. We also showed that focal KRAS amplifications can be acquired in tumor genomes of patients under cytotoxic chemotherapy. Furthermore, we provide evidence that specific chromosomal polysomies, such as overrepresentations of 12p and 7p, harboring KRAS and EGFR, respectively, determine responsiveness to anti-EGFR therapy.
- 27/05/2015
- 19 samples
- DAC: EGAC00001000072
- Technology: Illumina MiSeq
CTC - Plasma-DNA - MONDO:0005575
European Genome-Phenome Archivec/o European Bioinformatics InstituteWellcome Trust Genome CampusHinxtonCambridgeCB10 1SDUnited KingdomTo whom it may concern,This document refers to the study EGAS00001000337 which has been submitted to the European Genome Archive (EGA) for the restricted access by legitimate academic institutions that have agreed to comply with the terms of a Data Access Agreement drafted by Ellen Heitzer.There are a number of steps that a researcher must take to obtain access to this data and the process is overseen by Ellen HeitzerEllen Heitzer is a Postdoctoral Fellow and is authorized to approve researchers to have encrypted access to the data submitted to the EGA. Please be advised that Ellen Heitzer (ellen.heitzer@medunigraz.at) is authorized to upload data to the EGA for archiving and distribution as part of your submission process, which will enable approved researchers to have encrypted access to the data. We can confirm that this submission is consistent with the informed consent of the participants of the study or has been granted ethical approval and is in accordance with the applicable laws and regulations.Sincerely,Michael R. SpeicherPrinciple Investigator
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.
| ID | File Type | Size | Located in | |
|---|---|---|---|---|
| EGAF00000494660 | fastq.gz | 381.4 MB | ||
| EGAF00000494661 | fastq.gz | 524.7 MB | ||
| EGAF00000494662 | fastq.gz | 533.2 MB | ||
| EGAF00000494663 | fastq.gz | 461.0 MB | ||
| EGAF00000494664 | fastq.gz | 529.8 MB | ||
| EGAF00000494665 | fastq.gz | 469.7 MB | ||
| EGAF00000494666 | fastq.gz | 1.1 GB | ||
| EGAF00000494667 | fastq.gz | 550.5 MB | ||
| EGAF00000494668 | fastq.gz | 428.5 MB | ||
| EGAF00000494669 | fastq.gz | 1.3 GB | ||
| EGAF00000494670 | fastq.gz | 185.8 MB | ||
| EGAF00000494671 | fastq.gz | 540.1 MB | ||
| EGAF00000494672 | fastq.gz | 1.3 GB | ||
| EGAF00000494673 | fastq.gz | 828.2 MB | ||
| EGAF00000494674 | fastq.gz | 714.0 MB | ||
| EGAF00000494675 | fastq.gz | 541.6 MB | ||
| EGAF00000494676 | fastq.gz | 279.9 MB | ||
| EGAF00000494677 | fastq.gz | 523.1 MB | ||
| EGAF00000494678 | fastq.gz | 296.2 MB | ||
| 19 Files (11.5 GB) | ||||